Intrarosa at Work and in Daily Life: What Women Using Vaginal DHEA Need to Know

What Intrarosa Is and Why GSM Makes Work Harder Than It Should

Intrarosa is the brand name for prasterone, a synthetic form of DHEA (dehydroepiandrosterone) delivered as a 6.5 mg vaginal insert. The FDA approved it in November 2016 specifically for moderate-to-severe dyspareunia, the medical term for painful sex, as a symptom of genitourinary syndrome of menopause (GSM).

GSM affects an estimated 27 to 84 percent of postmenopausal women, a wide range that reflects how rarely women are asked about it. Symptoms extend well beyond the bedroom. Vaginal dryness, urinary urgency, recurrent urinary tract infections, and pelvic discomfort during prolonged sitting can all intrude on a standard workday.

How Prasterone Works Locally

Once inserted vaginally, prasterone is converted locally by vaginal cells into small amounts of estradiol and testosterone. This local conversion restores vaginal epithelial thickness, lowers vaginal pH, and improves lubrication without producing the systemic estrogen levels seen with oral or transdermal hormone therapy. The ERC-238 trial (also called the AMAG study), published in 2016, confirmed that blood levels of estradiol and testosterone in women using the 6.5 mg insert remained within the normal postmenopausal reference range across 52 weeks of nightly use.

Why This Matters for Women Who Avoid Systemic Estrogen

Many women at work-age perimenopause or postmenopause have been told to avoid systemic estrogen because of a personal or family history of estrogen receptor-positive breast cancer, blood clots, or personal preference. Because prasterone acts locally, The Menopause Society (formerly NAMS) notes in its 2023 position statement on hormone therapy that low-dose vaginal treatments, including vaginal DHEA, are associated with minimal systemic absorption and may be considered even in women with contraindications to systemic therapy, though anyone with a history of hormone-sensitive cancer should confirm this with their oncologist.

Fitting the Nightly Insert Into a Real Workday

The single biggest lifestyle question women ask about Intrarosa is practical: "How do I make a nightly vaginal insert part of my normal life without it becoming a project?"

The answer is largely about pairing, timing, and a realistic kit.

Pairing the Insert With an Existing Bedtime Habit

Prasterone works best when used every night at approximately the same time. A body of patient-reported data from the REJOICE trial program showed that consistent nightly use over 12 weeks produced statistically significant improvements in vaginal dryness and pain with sex versus placebo. Skipping doses slows the tissue-rebuilding process.

Pick a cue you already do: brushing your teeth, removing contact lenses, or taking a sleep supplement. Insert the presterone immediately after that cue. The pre-filled applicator takes roughly 30 seconds to use.

Shift Workers and Irregular Schedules

Shift work complicates "nightly." If you work rotating or night shifts, aim for consistency with your personal sleep window rather than clock time. Insert Intrarosa just before your main sleep period, whenever that falls. There is no published RCT evidence specifically in shift-working women, so this guidance extrapolates from the general pharmacological principle that local tissue effects accumulate with daily exposure rather than depending on a specific hour.

Staying Overnight Away From Home

Intrarosa does not require refrigeration. Store it at room temperature, below 30°C (86°F). A strip of inserts fits easily in a toiletry bag. Keep a small supply in your travel kit so a forgotten insert from your bathroom cabinet does not mean a missed dose. If you are flying, pack inserts in your carry-on rather than checked luggage to protect against lost bags.

What Colleagues, HR, and Insurance Actually Need to Know

Nothing. Intrarosa is a prescription inserted at home the night before work. Your employer has no medical claim to details about your GSM treatment. A few practical employment-adjacent points do matter.

Time Off for Prescription Pick-Up and Follow-Up

Most women on Intrarosa see their prescriber for a baseline visit, a 12-week follow-up, and then annual check-ins. If your workplace requires documentation for medical appointments, a standard appointment note suffices. No workplace accommodation is ordinarily needed for the drug itself.

Insurance and Prior Authorization

Intrarosa is covered by many commercial insurance plans but often requires a prior authorization (PA), which your prescriber initiates. The PA process can take 3 to 14 business days. Ask your prescriber to submit the PA at the time of the initial prescription so you are not waiting during a flare of symptoms. If insurance denies coverage, the manufacturer patient assistance program may reduce out-of-pocket costs; check the current terms directly with AbbVie (the current marketer) as program details change.

Telehealth Prescribing

Prasterone can be prescribed via telehealth in most U.S. States, which removes the need to take half a day off work for an in-person visit. Confirm that your state permits telehealth prescribing of scheduled compounds; DHEA itself is not a controlled substance in the United States, so most telehealth restrictions do not apply.

Pregnancy, Lactation, and Contraception: The Required Safety Conversation

This is one of the most under-discussed aspects of vaginal DHEA in clinical practice, partly because most trial participants were postmenopausal women aged 40 to 75. Here is what the evidence actually says, broken down by life stage.

Pregnancy

Intrarosa is contraindicated in pregnancy. The FDA label states this explicitly. DHEA is an androgen precursor; androgen exposure during pregnancy carries a theoretical risk of virilization of a female fetus, though no human teratogenicity data from vaginal prasterone exist. If there is any chance you could be pregnant, do not use Intrarosa until pregnancy is ruled out.

Perimenopausal women are a specific group at risk here. Perimenopause does not equal infertility. Ovulation can occur unpredictably even with irregular cycles. The ACOG Practice Bulletin on Contraception in Midlife Women recommends that perimenopausal women who do not want to conceive use reliable contraception until 12 months of amenorrhea have elapsed (postmenopause). If you are perimenopausal and starting Intrarosa, discuss concurrent contraception with your prescriber.

Lactation

Intrarosa is not indicated for premenopausal use in most clinical scenarios. No human lactation data on vaginal prasterone transfer into breast milk exist. The LactMed database does not list prasterone because it is not approved for use in reproductive-age women. Avoid use while breastfeeding.

Women in Perimenopausal Transition

The FDA approval is for postmenopausal dyspareunia due to GSM, but perimenopause produces the same vaginal estrogen deficiency and tissue changes, sometimes years before the final menstrual period. Off-label use in early perimenopause is an active clinical discussion. The 2023 Menopause Society position statement acknowledges that GSM can begin in perimenopause but notes that most GSM treatment trials enrolled postmenopausal women. The evidence base is therefore extrapolated to perimenopausal women rather than directly studied in them, which you deserve to know.

Who This Treatment Is Right For, and Who Should Pause

Understanding whether Intrarosa fits your life stage and health profile matters as much as understanding the daily logistics.

Women Likely to Benefit Most

• Postmenopausal women with moderate or severe dyspareunia and/or vaginal dryness confirmed to be GSM-related
• Women who prefer or require a non-systemic option because of personal history, oncologist guidance, or preference
• Women with recurrent urinary symptoms linked to GSM (urinary urgency, recurrent UTIs), though dyspareunia is the only FDA-approved indication
• Women who travel frequently and want a low-logistics, non-refrigerated treatment

Women Who Should Discuss Carefully First

• Perimenopausal women who are still potentially fertile (contraception discussion required, as above)
• Women with a current or recent hormone receptor-positive breast cancer diagnosis. The Endocrine Society and most oncology groups recommend discussing any hormonal or hormone-precursor treatment with the treating oncologist. The 2023 NAMS position statement is appropriately cautious here, noting that data on safety in breast cancer survivors are insufficient.
• Women with unexplained vaginal bleeding, which requires evaluation before starting any vaginal hormonal treatment
• Women currently using systemic DHEA supplements or testosterone therapy, given the additive androgen exposure

Women for Whom Intrarosa Is Contraindicated

• Pregnant women (contraindicated)
• Women with known or suspected estrogen-dependent neoplasia, per standard hormone-therapy cautions (discuss with your oncologist)

Side Effects That Could Show Up During Your Day

Most side effects from Intrarosa are local and occur at or near the time of insertion, which happens at night, making daytime disruption uncommon.

Vaginal Discharge

The most frequently reported side effect in clinical trials was vaginal discharge, reported by approximately 6.5 percent of women in the active arm of ERC-238. The discharge is typically white or off-white and related to the waxy suppository base. Wearing a thin panty liner during the first few weeks can prevent any spillage from appearing on clothing during your commute or workday. Most women find discharge decreases as the applicator technique improves.

Abnormal Pap Results and Cervical Cytology

DHEA's local conversion to estrogen causes vaginal maturation changes that can alter cervical cytology readings. Tell your gynecologist or nurse practitioner that you are using vaginal prasterone before any Pap test, because the changes in vaginal maturation index may otherwise prompt unnecessary follow-up. This is a communication issue, not a health risk, but it has real scheduling implications at work if it leads to unnecessary repeat testing.

Urinary Symptoms

Some women report transient urinary symptoms in the first few weeks. GSM itself causes urinary symptoms, and as vaginal tissue normalizes, these often improve. If new urinary burning or urgency appears and persists beyond four weeks, contact your prescriber to rule out a concurrent UTI.

What Is Not a Side Effect

Fatigue, brain fog, and mood changes are not listed as adverse effects in the Intrarosa label and were not significantly different from placebo in trial data. If you experience these symptoms, they are worth evaluating but are unlikely to be attributable to vaginal prasterone given its minimal systemic absorption profile.

Monitoring: What to Track and When to Report It

Because Intrarosa is used nightly for months to years, building a simple monitoring habit protects your health and makes follow-up appointments more efficient.

At-Home Tracking

Keep a brief symptom log, even a weekly note on your phone, covering:

• Pain with sex (a 0-10 scale is fine)
• Vaginal dryness severity at baseline and monthly
• Any new vaginal discharge that is yellow, green, or malodorous (which could indicate infection, not a drug effect)
• Urinary symptom frequency

The REJOICE trial used validated patient-reported outcome tools, but a simple personal scale works for monitoring your own trajectory. Women who track tend to notice whether improvement is on schedule (4 to 12 weeks for most) or whether something needs attention.

When to Contact Your Prescriber Between Appointments

Contact your prescriber if you notice:

• Vaginal bleeding (any amount, unexplained)
• Discharge that is purulent, foul-smelling, or associated with fever
• Pelvic pain that is new or worsening
• No improvement in dyspareunia after 12 weeks of consistent nightly use

Lack of response at 12 weeks is a signal to reassess the diagnosis. Not all dyspareunia is GSM; vulvodynia, pelvic floor dysfunction, and endometriosis require different treatment pathways. Women are sometimes left on a single treatment without reassessment. Push for that conversation.

Combining Intrarosa With Other GSM and Menopause Treatments

Prasterone can be used alongside non-hormonal lubricants and moisturizers. In fact, continuing a regular vaginal moisturizer (such as polycarbophil-based products, used 2 to 3 times weekly) while Intrarosa rebuilds vaginal tissue over the first 4 to 8 weeks may reduce discomfort during that ramp-up period.

Using Intrarosa Alongside Systemic HRT

Some postmenopausal women use both systemic menopausal hormone therapy (for hot flashes, sleep, or bone protection) and Intrarosa for focal vaginal symptoms. The 2023 Menopause Society position statement acknowledges that some women on systemic HRT still have persistent GSM and may need local vaginal therapy as well. The combination is used in clinical practice, but additive sex steroid exposure should be discussed with your prescriber, and monitoring may be more frequent.

Pelvic Floor Physical Therapy

Pelvic floor dysfunction frequently co-exists with GSM-related dyspareunia. A 2021 review in Menopause found that pelvic floor muscle training meaningfully reduced dyspareunia scores in postmenopausal women. Combining pelvic floor physical therapy with Intrarosa addresses both the tissue component and the muscular component. If your workplace has a flexible benefits account (FSA or HSA), pelvic floor PT is a qualifying medical expense.

The Evidence Gaps Women Deserve to Know About

Clinical trials for Intrarosa enrolled predominantly white, postmenopausal women aged 40 to 75 in North America. What that means concretely:

• Race and ethnicity: GSM symptom prevalence and treatment response may vary across ethnic groups. The SWAN study documented racial differences in menopausal symptom reporting, but Intrarosa's clinical trial data do not disaggregate by race in published summaries.
• Perimenopausal women: As noted above, this group was not the primary study population. Extrapolation from postmenopausal data is reasonable given the shared physiology of estrogen deficiency, but it is extrapolation.
• Long-term data beyond 52 weeks: The ERC-238 trial ran 52 weeks. Longer-term tissue effects, endometrial safety, and breast safety data for vaginal DHEA beyond one year are limited compared with the decades of data available for vaginal estrogen.
• Women with breast cancer: Evidence on safety in women currently receiving aromatase inhibitors or tamoxifen is sparse. One small study (Barton et al., 2018, published in JAMA Oncology) looked at vaginal DHEA in breast cancer survivors and found no significant change in systemic hormone levels over 4 weeks, but this was a pilot study and should not be treated as definitive safety clearance.

You deserve a prescriber who names these gaps rather than papering over them. Ask directly: "Is this extrapolated evidence or direct evidence for someone in my situation?"

A Note on DHEA Supplements Versus Prescription Prasterone

Over-the-counter oral DHEA supplements are widely available and entirely different from Intrarosa in mechanism, dose, and regulation. Oral DHEA raises systemic DHEA-S and downstream sex steroids throughout the body. Vaginal prasterone acts locally. The FDA has not approved any oral DHEA product for GSM. A 2018 systematic review in Maturitas found insufficient evidence to support oral DHEA for GSM symptoms. Do not substitute an over-the-counter supplement for prescription prasterone.